Positive Expression Rate Of Ki-67 Research Articles

Correlation between Ki-67 or Profilin-1 Expression Levels, Clinicopathological Characteristics and Postoperative Prognosis in Patients with Bladder Cancer.

Bladder cancer is the most common malignancy of the urinary system, and the search for new and reliable biomarkers has important clinical significance for the personalized treatment of bladder cancer. This study aims to explore the correlation between nuclear proliferation antigen (Ki-67) or Profilin-1 (PFN1) levels, clinicopathological characteristics, and postoperative prognosis in patients with bladder cancer. Patients with bladder cancer who underwent transurethral resection of bladder cancer tumor in The Fourth Affiliated Hospital of Soochow University, hospital from January 2019 to January 2021 were selected as the study group (n = 60), and patients with benign lesions of bladder cancer during the same period were selected as the control group (n = 60). The expression of Ki-67 and PFN1 in tumor and bladder tissues of the two groups was analyzed. Ki-67 recorded the patient's pathological parameters and calculated the patient's postoperative prognosis. The correlation between Ki-67 and PFN1 expression levels, pathological parameters, and postoperative prognosis was analyzed. The positive expression rates of Ki-67 and PFN1 in the study group were 63.33% and 73.33%, respectively, which were significantly higher than the positive expression rates in the control group (χ2 = 14.803, 17.757, p < 0.001). The positive expression rates of Ki-67 and PFN1 were related to histological grade, clinical stage, infiltration, and lymph node metastasis, and the differences were statistically significant (p < 0.05). Bladder cancer patients with non muscle-invasive bladder cancer (NMIBC), high-grade histological grade, Ta~T1 clinical stage, invasive, and lymph node metastasis have a higher Ki-67 positive expression rate than bladder cancer patients with muscle-invasive bladder cancer (MIBC), low-grade histological grade, T2~T4, non-invasive, and no lymph node metastasis. The high expression level of Ki-67 has little relationship with gender, age, tumor diameter, and vascular invasion (p > 0.05). The survival time and three-year survival rate of the Ki-67 positive expression group were significantly lower than those of the Ki-67 negative expression group (p < 0.05). The survival time and three-year survival rate of the PFN1 positive expression group were significantly lower than those of the PFN1 negative expression group (p < 0.05). The positive expression rates of Ki-67 and PFN1 in bladder tumor tissue are significantly higher than those in bladder tissue, and pathological pattern, histological grade, clinical stage, infiltration, and lymph node metastasis are related to the positive expression rates of Ki-67 and PFN1, and different genders, ages, tumors diameter and vascular invasion are not related to the positive expression rates of Ki-67 and PFN1. The survival time and three-year survival rates of bladder cancer patients with Ki-67 positive and PFN1 positive expression are shorter.

Circ_0007422 Knockdown Inhibits Tumor Property and Immune Escape of Colorectal Cancer by Decreasing PDL1 Expression in a miR-1256-Dependent Manner.

Circular RNAs (circRNAs) are a group of important molecules involved in the progression of various cancers, including colorectal cancer (CRC). Here, we aim to investigate the role and molecular mechanism of circ_0007422 in regulating CRC malignant progression. The expression levels of circ_0007422, miR-1256, and PDL1 were detected by qRT-PCR. Cell viability, proliferation, apoptosis, invasion, and self-replication ability were analyzed by CCK-8, EdU, flow cytometry, transwell, and spheroid formation experiments, respectively. Protein levels were determined by western blotting assay. CRC cells were co-cultured with CD8 + T cells, phytohemagglutinin-stimulated peripheral blood mononuclear cells (PBMCs), or cytokine-induced killer (CIK) cells in vitro, and CD8 + T-cell apoptosis, IFN-γ and TNF-α levels, and survival rate of CRC cells were analyzed to reveal the role of circ_0007422 in antitumor immunity. The relationship between miR-1256 and circ_0007422 or PDL1 was identified by a dual-luciferase reporter assay and RNA immunoprecipitation (RIP) assay. A xenograft tumor model was established to verify the function of circ_0007422 in tumor growth in vivo. Immunohistochemistry (IHC) assay was used to detect positive expression rates of Ki67, E-cadherin, N-cadherin, and PDL1 expression in primary tumors from CRC cells. Circ_0007422 was upregulated in CRC tissues and cells and its knockdown inhibited proliferation, invasion, self-replication ability, and immune escape and promoted apoptosis of CRC cells. Additionally, circ_0007422 bound to miR-1256, which was identified to target PDL1. MiR-1256 inhibition reversed the effects of circ_0007422 knockdown on the tumor properties and immune escape of CRC cells. Moreover, miR-1256 introduction interacted with PDL1 to suppress proliferation, invasion, self-replication ability, and immune escape and promote apoptosis of CRC cells. Further, circ_0007422 knockdown hampered tumorigenesis of CRC cells in vivo. Circ_0007422 knockdown inhibited tumor property and immune escape of colorectal cancer through the miR-1256/PDL1 pathway, providing a potential novel therapeutic target for CRC.

Association between different types of preoperative anemia and tumor characteristics, systemic inflammation, and survival in colorectal cancer.

Patients with colorectal cancer often have anemia and other symptoms after diagnosis, especially in patients with advanced colorectal cancer. This study explored the association between different types of preoperative anemia and tumor characteristics and inflammatory response in patients with colorectal cancer and to evaluate the prognosis of patients with different types of anemia before operation. The clinical data of 95 patients with colorectal cancer treated in the Fourth Hospital of Hebei Medical University from February 2016 to January 2018 were retrospectively analyzed. According to the hemoglobin concentration (Hb), mean corpuscular volume (MCV), mean hemoglobin content (MCH) and mean hemoglobin concentration (MCHC), the patients were divided into the non-anemia group, normal cell anemia group, and small cell anemia group. The three groups' general data, oncological characteristics, and mGPS scores were compared. The patients were followed up for five years, and the survival analysis was carried out. The cox proportional hazard regression model was used to analyze the prognostic factors of patients with colorectal cancer. The preoperative anemia rate of patients with colorectal cancer was 43.15% (41/95). There were significant differences in gender, weight loss, CA724, tumor location, tumor size, TNM stage, mGPS score, and positive expression rate of Ki-67 among different anemia groups. There was a significant difference in survival time among a non-anemia group, small cell anemia group, and normal cell anemia group (P<0.05). Multivariate analysis showed that tumor size, TNM stage, distant metastasis, mGPS score, Ki-67 positive expression rate, and anemia type were independent risk factors affecting the prognosis of colorectal cancer patients (P<0.05). The oncological characteristics of colorectal cancer patients with different types of preoperative anemia are different. Preoperative anemia and systemic inflammatory status are independent risk factors for the prognosis of colorectal cancer patients.

Hsa_circRNA_0017620 regulated cell progression of non-small-cell lung cancer via miR-520a-5p/KRT5 axis.

BackgroundCircRNA is a very important functional RNA that plays an important role in the development and metabolism of cancer. However, the study of circRNA in NSCLC has not been fully elucidated.MethodsThe expression of hsa_circ_0017620, SFMBT2, miR‐520a‐5p, and KRT5 was determined using qRT‐PCR. KRT5, Twist1, E‐cadherin, and Ki67 protein expression were measured with western blot. The positive expression rates of Ki67 and Vimentin were determined by immunohistochemistry assay. 5‐Ethynyl‐2’‐deoxyuridine (EdU), colony formation, and MTT assays were used to assess cell proliferation. Transwell migration and invasion assay were applied to determine cell migration and invasion. Dual‐luciferase reporter and RNA immunoprecipitation assays were used to verify the relationship among hsa_circ_0017620, miR‐520a‐5p, and KRT5. The animal experiment was used to ensure the effects of hsa_circ_0017620 on tumor growth in vivo.ResultsHsa_circ_0017620 was upregulated in NSCLC cells and tissues. MiR‐520a‐5p had been verified to be a target miRNA of hsa_circ_0017620 and KRT5 had been verified to be a target mRNA of miR‐520a‐5p in NSCLC cells. Knockdown of hsa_circ_0017620 inhibited cell proliferation, migration, and invasion in NSCLC cells, which was reversed by downregulating miR‐520a‐5p or upregulating KRT5 in NSCLC. Overexpression of hsa_circ_0017620 had opposite effects in NSCLC. Moreover, hsa_circ_0017620 silencing inhibited tumor growth in vivo of NSCLC.ConclusionIn this study, we found that hsa_circ_0017620 played an important role in NSCLC progression. Hsa_circ_0017620 regulated cell proliferation, invasion, and migration through targeting miR‐520a‐5p/KRT5 axis in NSCLC, providing a potential new target for the treatment and diagnosis of NSCLC.

Expression and significance of mammalian target of rapamycin in cutaneous squamous cell carcinoma and precancerous lesions

ABSTRACT The aim of this study is to explore the role of mammalian target of rapamycin (mTOR) in cutaneous squamous cell carcinoma (CSCC), Bowen’s disease (BD), and actinic keratosis (AK) with squamous cell differentiation abnormality and its relationship with the degree of tumor proliferation. Thirty cases of clinical paraffin specimens of CSCC, BD, and AK were each collected from Jinhua Fifth Hospital, while 30 cases of normal skin specimens surgically resected in Department of Plastic Surgery were selected as controls. The expressions of mTOR and Ki-67 in tissues were detected by immunohistochemical staining. The positive expression rate of mTOR in the CSCC group was higher than those in the BD group and AK group (P < 0.05), while it was higher in the BD group and AK group than in the normal skin group (P < 0.05). The CSCC group had a higher positive expression rate of Ki-67 than the AK group (P < 0.01). The results of logistic regression analysis showed that the pathogenic site [odds ratio (OR) = 1.189, 95% confidence interval (95%CI): 1.028–1.381, P = 0.021], course of disease (OR = 2.059, 95%CI: 1.036–4.087, P = 0.043), and differentiation degree (OR = 1.325, 95%CI: 1.169–1.512, P = 0.001) were independent factors for the positive expression of mTOR. OR>1, indicating that the factor is a risk factor. The expression levels of mTOR in CSCC, BD, and AK were positively correlated with the expression level of Ki-67 (r = 0.827, P < 0.01, r = 0.608, P < 0.01, r = 0.368, P = 0.045). These results suggest that mTOR may be involved in the pathogenesis of CSCC, and related to the proliferation degree of CSCC, as an index reflecting the proliferation status of CSCC.

Correlation analysis of Ki67 and CK7 expression with clinical characteristics and prognosis of postoperative cervical adenocarcinoma patients.

The purpose of this study is to investigate the correlation between cytokeratin 7 (CK7) and marker of proliferation Ki67 protein expression and clinical characteristics and prognosis of patients with cervical adenocarcinoma after surgery. A total of 126 patients with cervical adenocarcinoma treated by surgery in our hospital from June 2011 to September 2015 were enrolled in this study. Immunohistochemistry (IHC) was used to detect the expression of CK7 and Ki67 in 126 cases of cervical adenocarcinoma tissues. The chi-square (χ2) test was used to compare the relationship between the positive expression rate of CK7 or Ki67 and clinicopathological features. Kaplan-Meier method was used to analyze the survival of different protein expression groups and Cox proportional hazards regression model was used to analyze the risk factors affecting the prognosis. The positive rate of CK7 was correlated with muscle invasion, vascular invasion, differentiation, and lymph node metastasis (all P<0.05). The positive expression rate of Ki67 was related to the degree of myometrial invasion and International Federation of Gynecology and Obstetrics (FIGO) stage (both P<0.05). Both CK7 and Ki67 may be independent risk factors for the prognosis of patients with cervical adenocarcinoma after surgery (both P<0.05), and their high expression heralds worse prognosis. The CK7 and Ki67 proteins may be key regulatory factors in the development of cervical adenocarcinoma after surgery, and their overexpression may lead to worse prognosis. Both CK7 and Ki67 may provide new markers for prognosis evaluation of cervical adenocarcinoma.

The prognostic relevance of p53 and Ki-67 to chemotherapy sensitivity and prognosis in triple-negative breast cancer.

BackgroundThis study aimed to explore the prognostic function of p53 and Ki-67 protein expression in chemotherapy sensitivity and prognosis in triple-negative breast cancer (TNBC).MethodsPatients who were confirmed with TNBC in Wenzhou Geriatric Hospital and Wenzhou Hospital of Traditional Chinese Medicine (including the Oncology Department, Tumor Surgery Department, and Gynecology Department) between January 2006 and February 2018 were included in this study. The expression of p53 and Ki-67 detected by immunohistochemistry, the rate of recurrence, and the objective curative effect evaluation at the end of the first-line rescue treatment were recorded for all patients.ResultsThe patients were followed up to August 2020, and the median follow-up time was 9 years and 4 months. A total of 285 patients with TNBC were enrolled in the study. The patients ranged in age from 19 to 76 years old, with an average age of 53 years. The overall recurrence rate among the patients was 31.58%. The majority of cases (68.07%) were pathological stage I. The overall positive expression rates of Ki-67 and p53 were 53.33% and 56.84%, respectively. In the TNBC recurrence group, the positive rates of p53 and Ki-67 were 71.11% and 82.22%, respectively, which were significantly higher than those in the non-recurrence group. The positive rates of p53 and Ki-67 in the chemosensitive group were 96.05% and 92.11%, respectively, which were significantly higher than those in the non-chemosensitive group. Among all the TNBC patients, 128 patients had positive expression of both p53 and Ki-67, and 101 patients had negative expression of both p53 and Ki-67. The chemosensitivity rate of TNBC patients with positive expression of both Ki-67 and p53 was 98.53%, and that of TNBC patients with negative expression of both Ki-67 and p53 was 0.00%. The difference was statistically significant. The recurrence rate in TNBC patients with positive expression of both Ki-67 and p53 was 53.13%, and that in patients with negative expression of both Ki-67 and p53 was 6.93%. The difference was statistically significant.ConclusionsThe expression of p53 and Ki-67 had prognostic relevance to chemotherapy sensitivity and prognosis in TNBC patients.

Polyphenol-Enriched Extracts from Trapa acornis Husks Inhibit Her2-Positive SK-BR-3 Breast Cancer Cell Proliferation and In Vivo Tumor Angiogenesis

The study aimed to investigate the antitumor effects of Trapa acornis husks (TAH) extract on SK-BR-3 cells of Her2-positive breast cancer. The bioactive compounds of TAH extracts were analyzed qualitatively and quantitatively by Ultra-Performance Liquid Chromatography/Mass Spectrometry (UPLC-MS)/high-performance liquid chromatographic system (HPLC). The effects of TAH extracts on cell proliferation, cell cycle, and apoptosis of SK-BR-3 cells were determined by CCK-8 and flow cytometry. Besides, the In Vivo antitumor effect of TAH extracts was detected. UPLC-MS/HPLC showed that the main bioactive compounds of TAH were gallic acid and galloylglucose derivatives. TAH extracts significantly inhibited the proliferation of SK-BR-3 cells in a dose- and time-dependent manner (P < 0.01). With the increase of TAH extracts concentration, cells in G2/M stage were increased and cell apoptosis was significantly increased. Immunohistochemical analysis showed that TAH extracts can significantly reduce the positive expression rate of Ki67 and Factor VIII index in tumor tissues. The mRNA expression levels of VEGF, MMP2, MMP9, and uPA were reduced after TAH extracts intervention (P < 0.01). TAH extracts also decreased the protein expression of p-Her2, p-ERK1/2, VEGF, MMP2, MMP9, and uPA (P < 0.01). In conclusion, polyphenol-enriched extracts from TAH might inhibit breast cancer cell proliferation and In Vivo tumor angiogenesis.

Betulinic acid enhanced the chemical sensitivity of esophageal cancer cells to cisplatin by inducing cell pyroptosis and reducing cell stemness.

Betulinic acid (BA) is a lupine pentacyclic triterpene compound derived from the bark of the white mulberry tree, which has a variety of pharmacological properties. The purpose of this study was to investigate the effects of BA combined with cisplatin on the proliferation, stemness, pyroptosis, and xenograft growth of esophageal carcinoma cells in a nude mouse xenograft model. The cell survival rate was detected by CCK-8 method. TE-11 cells were treated with 3μM of BA and 15 μM of cisplatin. The cells were randomly divided into four groups: the control group, the BA group, the cisplatin group, and the BA + Cisplatin group. Western blotting was used to detect the expression levels of Ki67, PCNA, SOX2, OCT4, ASC, and Caspase-1. The xenograft model of nude mice was constructed to detect tumor volume, and the positive expression rates of Ki67 and Caspase-1 were detected by immunohistochemistry. Compared with the control group, Ki67, PCNA, SOX2, and OCT4 levels in the BA and cisplatin groups were significantly lower (P<0.05), while ASC and Caspase-1 levels were significantly higher (P<0.05). Compared with the BA group, Ki67, PCNA, SOX2, and OCT4 levels in the BA + cisplatin group were significantly lower (P<0.05), while ASC and Caspase-1 levels were significantly higher (P<0.05). In the nude mouse xenograft model, compared with the control group, the tumor volume of the BA and cisplatin groups was significantly decreased (P<0.05), the expression rate of Ki67 was significantly decreased (P<0.05), and the expression rate of Caspase-1 was significantly increased (P<0.05). Compared with the BA group, the levels of ASC and Caspase-1 in the BA + cisplatin group were significantly lower (P<0.05), the positive expression rate of Ki67 was significantly lower (P<0.05), and the positive expression rate of Caspase-1 was significantly higher (P<0.05). BA enhances the chemical sensitivity of esophageal cancer cells to cisplatin by inhibiting cell proliferation, reducing cell stemness, and inducing pyroptosis.

MMP2、TIMP2、Ki-67、P53在胶质瘤组织中的表达及意义

Objective To investigate the expressions and significance of matrix metalloproteinase 2 (MMP2), tissue inhibitor of metalloproteinase 2 (TIMP2), Ki-67 and P53 in human glioma tissues. Methods The expressions of Ki-67 and P53 in paraffin samples of 50 gliomas (immunohistochemistry SP method) from January 1995 to December 2015 in Qilu Hospital of Shandong University were analyzed retrospectively, and the expressions of MMP2 and TIMP2 were detected by immunohistochemistry. The differences of parameters between high- and low-grade gliomas were compared by χ2 test and their correlations were assessed by Spearman correlation analysis. Results In the high-grade group (grade Ⅲ-Ⅳ, n=37), the high expression rate of MMP2 was 81.08% (30/37), the positive expression rates of Ki-67 and P53 were 78.38% (29/37) and 72.97% (27/37). In the low-grade group (grade Ⅰ-Ⅱ, n=13), there were 2 patients with high expression of MMP2, 3 patients with positive expression of Ki-67 and P53 respectively, and there were significant differences between the two groups (χ2=15.282, P<0.001; χ2=10.482, P=0.001; χ2=9.979, P=0.002). A significant correlation was found between them and pathological grade (r=0.600, P<0.001; r=0.505, P<0.001; r=0.447, P=0.001). The high expression of TIMP2 was found in 8 cases of low-grade group and 19 cases (51.35%) of high-grade group, with no significant difference (χ2=0.402, P=0.526). The expression of MMP2 was positively correlated with Ki-67 and P53 (r=0.392, P=0.005; r=0.323, P=0.022), while TIMP2 was negatively correlated with Ki-67 (r=-0.441, P=0.001). The expression of P53 was positively correlated with Ki-67 (r=0.748, P<0.001). Conclusion MMP2, Ki-67 and P53 may play important role in the proliferation and invasiveness of glioma. The mechanism of TIMP2 is complicated and needs further study. Key words: Glioma; Matrix metalloproteinase 2; Tissue inhibitor of metalloproteinase 2; Ki-67 antigen; Tumor suppressor protein P53

Expression of PCNA, Ki-67 and COX-2 in breast cancer based on DCE-MRI image information

In order to explore the application value of DCE-MRI in clinical diagnosis and treatment, guide early clinical diagnosis, evaluate prognosis, guide clinical selection of treatment options and improve medical level, the expression of adenocarcinoma, its relationship with clinicopathology, and the significance of co-expression of the proliferating cell nuclear antigen (PCNA), Ki67 protein and cyclooxygenase 2 (COX-2) in breast cancer are analyzed. The results show that the positive expression rates of ki67, PCNA, and COX-2 in breast cancer patients are significantly higher than those in breast cancer patients (P<0.05). Positive expressions of ki67, PCNA, and COX-2 in breast cancer patients are not correlated with age, tumor size and clinical stage (P>0.05). There is no significant difference (P>0.05) between the pathological types of breast cancer and positive expressions of ki67, PCNA and COX-2 in all the samples studied. Therefore, there is a correlation between DCE-MRI imaging features and prognostic indicators in breast cancer.

Expressions of Topo IIα and Ki67 in breast cancer and its clinicopathologic features and prognosis.

Objective:Breast cancer is one of the most common malignant tumors in women, and its incidence in women has ranked the first place among all malignant cancers. The evolution of breast cancer which is highly heterogeneous is a complex biological process involving multiple factors, genes and stages. Therefore, studying the expression and interaction of related genes is of great significance to further revealing of the mechanism of the occurrence and development of breast cancer and reduction of its resistance to chemotherapy. The purpose of this study was to investigate expressions of Ki67 and Topoisomerase IIα (Topo IIα) in breast cancer tissues and to explore the relationship between expressions of Ki67 and Topo IIα and the pathological characteristics and prognosis of breast cancer.Methods:Tissues with pathological changes and peripheral normal breast tissues were collected from 66 patients who underwent breast cancer treatment. Ki67 and Topo IIα in the breast cancer tissues and normal breast tissues were detected using immunohistochemical method. The relationships of Ki67 and Topo IIα with general clinicopathologic features and prognosis were analyzed.Results:It was found that the positive expressions of Ki67 and Topo IIα in the breast cancer tissues were higher than those in the normal tissues; the positive expression rate of Ki67 was in a correlation with diameter of breast cancer and lymphatic metastasis (P<0.05); the positive expression rate of Topo IIα was in a correlation with clinical stage, diameter of cancer and lymphatic metastasis (P<0.05). Multi-factor logistic regression analysis suggested that lymphatic metastasis and clinical stage were the independent predictive factors for positive expression of Topo IIα and lymphatic metastasis was the independent predictive factor for positive expression of Ki-67. Breast cancer patients with negative Ki67 and Topo IIα had significantly higher local recurrence rate than those who had positive Ki67 and Topo IIα (P<0.05) after surgery. The median time to progression (TTP) of the patients with positive expression of Topo IIα was lower than that with negative expression (P<0.05). The median TTP of the patients with negative and positive expression of Ki67 had no significant difference (P>0.05).Conclusion:Topo IIα and Ki67 can be used for reflecting the proliferation activity of cancer cells and can affect the postoperative recurrence and survival time after surgery. They may be involved in the occurrence, development and metastasis of breast cancer. They are expected to be indicators in the prognosis prediction of breast cancer and potential treatment targets.

Study on the expression of hormone receptor and human epidermal growth factor receptor 2 in breast cancer primary tumor and axillary lymph node metastasis

Objective To explore the expression of HR and Her-2 in breast cancer primary tumor and axillary lymph node metastasis. Methods Four hundred and twenty-eight female patients with unilateral breast cancer combined with axillary lymph node metastasis treated in the Affiliated Suqian Hospital of Xuzhou Medical University from January 2011 to January 2016 were selected in this study.Immunohistochemistry was used to detect the expression of ER, PR, Her-2 and Ki67 in primary tumor and axillary lymph node metastasis. Results The positive rates of ER expression were 75.9% (325/428) and 70.3% (301/428) respectively in primary tumor and axillary lymph node metastasis.The positive rates of PR expression were 61.4% (263/428) and 56.1% (240/428) respectively in primary tumor and axillary lymph node metastasis.The rates of Her-2 overexpression were 20.1% (86/428) in primary tumor and the positive rate of Her-2 in axillary lymph node metastasis was 22.7%(97/428). The positive rates of Ki67 expression were 45.6%(195/428) and 39.7%(170/428) respectively in primary tumor and axillary lymph node metastasis.The expression of ER, PR, Her-2 and Ki67 in primary and axillary lymph node metastasis showed no statistical significance (P>0.05). The molecular typing of primary tumor and axillary lymph node metastasis were not consistent in 31 patients (31/428, 7.24%), including 14 cases of primary tumor Luminal A, 9 cases of Her-2 overexpression in axillary lymph node metastasis and 5 cases of triple negative breast cancer.Primary tumor Luminal B was detected in 10 cases, while 6 cases of Her-2 overexpression in axillary lymph node metastasis and 4 cases of triple negative breast cancer.Primary tumor Her-2 was overexpressed in 4 cases, while 1 case of Luminal A, 3 cases of Luminal B in axillary lymph node metastasis.There were 3 cases of primary tumor triple negative breast cancer, while 2 cases of Luminal B in axillary lymph node metastasis and 1 case of Her-2 overexpression. Conclusion The expressions of ER, PR, Her-2 and Ki67 in primary tumor and axillary lymph node metastasis of some breast cancer were different.Immunohistochemistry for primary tumor and axillary lymph node metastasis of stage II-III breast cancer patients should be routinely carried out.Based on molecular typing of primary tumor and axillary lymph node metastasis, individualized treatment plan can be developed, so that patients will benefit from it. Key words: Breast Cancer; Primary tumor; Axillary lymph node metastasis; Molecular typing; Estrogen receptor; Progesterone receptor; Human epidermal growth factor receptor-2; Proliferating cell nuclear antigen Ki67

Expression and clinical significance of Ki-67, E-cadherin, and mesothelin in serous borderline ovarian tumor.

This study aimed to investigate the expression of Ki-67, epithelial cadherin (E-cadherin), mesothelin, and their correlations with clinicopathological features of serous borderline ovarian tumors (SBOTs). Immunohistochemistry was conducted to investigate the expression of a cellular proliferation-related factor (Ki-67) and metastasis-related factors (E-cadherin and mesothelin) in 41 cases of SBOTs, 30 benign ovarian tumor tissues, and 30 malignant ovarian tumor tissues. The results showed that the expression rate of Ki-67 (46.3%) in SBOTs was higher than that in benign tumors (6.7%), but lower than that in ovarian carcinomas (80%). SBOTs significantly differed from benign ovarian tumors (p < 0.01) and carcinoma (p < 0.01). The positive expression rate of Ki-67 was significantly correlated with FIGO stage and peritoneal implantation of SBOTs (p < 0.01). The expression rate of E-cadherin was significantly lower in ovarian carcinomas (56.7%) than in SBOTs (80.5%) and benign ovarian tumors (90%; p < 0.05). The mesothelin expression in ovarian carcinomas and SBOTs significantly differed from that in benign ovarian tumors (p < 0.01). The positive expression rate of mesothelin was related to the serum CA125 level (p < 0.05). The expression of Ki-67 was positively correlated with the expression of E-cadherin and mesothelin in SBOTs. SBOTs generally behave in a benign manner. Ki-67, E-cadherin, and mesothelin may play an important role in the oncogenesis and progression of SBOT. Patients with Ki-67 and mesothelin overexpression and low E-cadherin expression should be followed up.

Application value of detection on stathmin, p16 and Ki-67 in the cervical intractable cases

Objective To investigate the clinical application value of stathmin, p16 and Ki-67 in the cervical intractable cases. Methods Immunohistochemical method was used to detect the expressions of stathmin, p16 and Ki-67 in surgical specimens of 288 cervical intractable cases, including 30 cases of cervical benign changes, 70 cases of cervical intraepithelial neoplasia (CIN) Ⅰ, 78 cases of CINⅡ, 85 cases of CIN Ⅲ and 25 cases of squamous cell carcinoma (SCC, as control group). The application value of stathmin, p16 and Ki-67 in the cervical cases were analyzed. Results The positive expression rates of Ki-67 of cervical benign changes and CINⅠwere 20.0 % (6/30) and 54.3 % (38/70) (χ2 = 3.29, P > 0.05). The expression rates of Ki-67 in CINⅡ, CINⅢ and SCC were all 100.0 %, and compared with the cervix benign changes, the differences were statistically significant (χ2= 112, P 0.05), but the expression rates in CINⅢ and SCC were higher than those in cervical benign change, CIN Ⅰand CIN Ⅱ(P < 0.01). The positive expressions of stathmin, p16 and Ki-67 in each group of CIN were positively correlated (r = 0.412, P < 0.05). Conclusions Combined detection of p16 and Ki-67 can assist in the differential diagnosis of cervical intractable cases, and provide objective indicators for the classification and accurate diagnosis of CIN. Combined detection of p16 and stathmin may help to identify high-grade, low-grade CIN and cervix benign changes for the reduction of over-treatment. Key words: Cervical intraepithelial neoplasia; Uterine cervical diseases; Stathmin; p16; Ki-67; Diagnosis

[Application value of fine needle aspiration and cell block in preoperative diagnosis of thyroid cancer and discrimination of follicular tumor].

To study the application value of fine needle aspiration and cell block combined with molecular markers in early diagnosis of thyroid cancer and discriminate follicular tumor before operation. Fine needle biopsy of thyroid nodules was guided by color ultrasound, then the sample acquired was used to make smear and the rest to make cell block. The pathological diagnosis on smear, cell block or combination of both was made respectively. Then, the Envision immunohistochemical method was employed to detect the expressions of CK19, Galectin-3 in cell block samples, which had been used for the diagnosis of papillary thyroid carcinoma or thyroid nodules from benign lesions after operation and to detect the expressions of DDIT3, ki-67 of cell block that had been used for the diagnosis of follicular tumor nodules. The sensitivity, specificity, positive predictive value, negative predictive value and accuracy of cytopathology for the diagnosis of malignancy were 95.3%, 94.7%, 92.7%, 96.6% and 95.0% respectively; and the sensitivity, specificity and accuracy of the diagnosis used cell block alone or combined with smear were 88.1%, 95.3%, 92.3% and 95.3%, 94.7%, 95.0% respectively, which were higher than 53.8%, 83.7%, 71.3% from smear correspondingly. The positive expression rate of CK19 and Galectin-3 of papillary thyroid carcinoma cell block were 100% and 98.0% respectively, higher than the value 17.7% and 23.3% of thyroid benign lesions (P < 0.01); the positive expression rate of DDIT3 of thyroid follicular cancer cell block was 84.6%, higher than the value 35.1% of follicular adenoma (P < 0.01), there was no statistical significance of Positive expression rate of Ki-67 between thyroid follicular carcinoma and follicular adenoma cell block (P > 0.05). It was conducive to early diagnose thyroid cancer with detection of CK19, Galection-3 of cell block made by ultrasound-guided fine needle biopsy of thyroid nodules. And it was also significant for DDIT3 detection to early discriminate follicular neoplasm before operation.

Expression of plexinA1 and Ki-67 in tissue of patients with human glioma cells and their clinical significance

Objective To explore expression of plexinA1 and Ki-67 in tissue of human brain glioma cells and their clinical significance. Methods 43 specimens from patients with brain glioma were collected. Immunohistochemical(IHC) staining was used for detecting the expression of tissue plexinA1 and Ki-67 in human glioma cells of 43 cases of patients with brain glioma. The positive expression rate of plexinA1 and Ki-67 among the different pathological grade tissues and their clinical significance were analyzed. So did correlation studies about plexinA1 and Ki-67. Results The positive expression rates of plexinA1 in Ⅰ-Ⅱ grade group(18 cases) and Ⅲ-Ⅳ grade group (25 cases) were 22.22 % (4/18) and 72.00 % (18/25) (P<0.05). The positive expression rates of Ki-67 in Ⅰ-Ⅱ grade group and Ⅲ-Ⅳ grade group were 16.67 % (3/18) and 56.00 % (14/25), respectively (P<0.05). PlxinA1 and Ki-67 expression in the tissue of human brain glioma were positively correlated (r=0.997, P<0.05). Conclusions The positive expression rate of plexinA1 is higher in high malignancy human glioma group than that in low malignancy group which has an important reference value in the estimation of prognosis for human glioma. PlexinA1 and Ki-67 maybe synergism in occurrence and development of glioma. Key words: plexinA1; Ki-67; Glioma; Prognosis

Expressions and their Significance of Ki-67, p53, and survivin in esophageal cancer and precancerosis

Objective To investigate the expressions and clinical significance of Ki-67, p53, and survivin in esophageal cancer and precancerosis. Methods The expressions of Ki-67, p53, and survivin proteins were detected by immunohistochemical staining in 40 normal esophageal mucosa, 136 precancerosis (42 mild atypical hyperplasia, 43 moderate atypical hyperplasia, and 51 severe atypical hyperplasia), and 68 esophageal cancer tissues. The correlation of three proteins expressed in esophageal carcinoma tissues was analyzed. Results The positive expression rate of Ki-67 was 0 (0/40)for normal epithelium, 35.7% (15/42) for mild dysplasia, 51.2% (22/43) for moderate dysplasia, 74.5% (38/51) for severe dysplasia, 92.6% (63/68) for squamous carcinoma, respectively. The positive expression rate of p53 protein was 0 (0/40) for normal epithelium, 28.6% (12/42) for mild dysplasia, 46.5% (20/43) for moderate dysplasia, 52.9% (27/51) for severe dysplasia, 67.6% (46/68) for squamous carcinoma, respectively. The positive expression rate of survivin protein was 0 (0/40) for normal epithelium, 38.1% (16/42) for mild dysplasia, 55.8% (24/43) for moderate dysplasia, 64.7% (33/51) for severe dysplasia, 89.7% (61/68) for squamous carcinoma, respectively. Rank correlation analysis showed that abnormal expressions of Ki-67, p53, and survivin were correlated significantly with the pathological grading of the lesions (r=0.637, 0.454, 0.590, P<0.01). The expressions of Ki-67, p53, and survivin were positively correlated in esophageal carcinoma (r=0.407, 0.646, P<0.01). Conclusions The abnormal expressions of Ki-67, p53, and survivin were associated with the processes of the esophageal canceration, and the joint detection with three parameters has important clinical value. Key words: Esophageal neoplasms/ME; Esophageal diseases/ME; Ki-67 antigen/ME; Genes, p53; Microtubule-associated proteins/ME

The expression and significance of proliferation cell nuclear antigen in renal cell carcinoma

Objective To explore the clinical significance of proliferation cell nuclear antigen (Ki-67) expression in renal cell carcinoma (RCC).Methods The immunohistochemistry staining method was used to evaluate the expression of Ki-67 in 70 cases of RCC and 30 cases of normal renal tissue as controls.Results The positive expression rate of Ki-67 was 64.29％ in RCC.The positive expression rate of Ki-67 in RCC was significantly related to the clinical stage or clinical grade (P ＜ 0.05),but not to the types of RCC (P ＞0.05).Conclusion Ki-67 is an objective marker to estimate the behaviors of RCC. Key words: Renal cell carcinoma;  Proliferation cell nuclear antigen;  Biological behavior

Ki67 as a predictor of poor prognosis in patients with triple-negative breast cancer.

The aim of the current study was to investigate the expression of the proliferation antigen, Ki67, in triple-negative breast cancer (TNBC) and its correlation with clinicopathological factors. The expression of Ki67 and other biological indicators in 24 cases of TNBC tissues and 178 cases of non-TNBC tissues were detected using immunohistochemistry. Their correlation with the clinicopathological factors were also analyzed using the χ2 test. The positive rate of Ki67 expression in TNBC tissues was 83.3%, exhibiting a statistically significant difference when compared with that in non-TNBC tissues (73.0%) (P<0.05). The expression of Ki67 in breast cancer tissue significantly correlated with the tumor size and lymph node metastases; however, no correlation was observed with the age and the clinical stage. Ki67 may be an indicator of poor prognosis in TNBC patients.